Two of the best-known mitochondria-targeted compounds were put head-to-head in the same fatty-liver model, and they did not do the same thing. MitoQ leaned toward antioxidant defense. SS-31 (elamipretide) leaned toward protecting mitochondrial structure. Both reduced liver fat and inflammation.
Important up front: this is a mouse study. It used aged female C57BL/6 mice, not people. Nothing here is a human dosing guide or evidence that either compound treats fatty liver in humans.
The Study at a Glance
The work, by Xiao and colleagues at Shandong University-affiliated Public Health Clinical Center and published in Physiological Research (2026), asked a practical question. Mitochondrial dysfunction is widely seen as an early driver of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). There is still no broadly approved drug for it, so which mitochondria-targeted strategy looks better in a stressed, aged liver?
The design:
- Animals: aged female C57BL/6 mice, 12-14 months old
- Diet: high-fat, high-fructose for 16 weeks to induce MASLD
- Groups: (1) control diet, (2) untreated MASLD, (3) MASLD + MitoQ, (4) MASLD + SS-31
- MitoQ: 25 mg/kg/day, oral
- SS-31: 3 mg/kg/day, intraperitoneal injection
The researchers measured liver proteins by western blot and assessed fat accumulation with H&E histology.
What Each Compound Is
MitoQ is a modified form of coenzyme Q10 (ubiquinone) attached to a triphenylphosphonium cation. That positively charged tag lets it accumulate inside mitochondria, where it can act as an antioxidant at the site where reactive oxygen species are produced. It is sold as an oral dietary supplement in many markets.
SS-31 (elamipretide) is a small synthetic tetrapeptide from the Szeto-Schiller family. It is thought to associate with cardiolipin, a phospholipid found in the inner mitochondrial membrane, and help stabilize cristae architecture and electron-transport efficiency. Rather than scavenging radicals directly, it is usually described as supporting the structure that keeps respiration efficient. It has been studied in clinical trials for mitochondrial and cardiac conditions and is a drug-development compound, not a supplement.
What Both Compounds Did
Compared with untreated MASLD mice, both treatments produced broadly similar improvements:
- Mitochondrial biogenesis markers: higher PGC-1α, NRF1, and TFAM, which are central to making and maintaining mitochondria
- Inflammation: lower NF-κB and NLRP3 inflammasome activation
- Insulin signaling: higher p-Akt and GLUT2
- Liver histology: marked reductions in steatosis on H&E staining
The authors also describe reduced fibrosis-related signaling, though the abstract frames this mainly through inflammatory and fibrotic mediators rather than detailed scarring measures.
The convergence is notable because the two molecules work through different mechanisms. It suggests the broader mitochondrial-health pathway may matter more than any single mechanism.
Where They Differed
MitoQ: stronger antioxidant signature. MitoQ more clearly upregulated SOD2 (the main mitochondrial superoxide dismutase) and Nrf2 (a master regulator of antioxidant genes). It also lowered 4-HNE adducts, a marker of lipid peroxidation. This fits its design as a mitochondria-localized antioxidant.
SS-31: better structural preservation. SS-31 was more effective at preserving mitochondrial structural integrity. That is consistent with its proposed cardiolipin-based mechanism, which targets membrane architecture more than redox chemistry.
These are differences in emphasis, not a clean winner. Which profile is more useful depends on what you think is driving the disease at a given stage: oxidative damage, membrane and structural breakdown, or both.
What This Doesn't Prove for Humans
This kind of study is useful for generating hypotheses, but the limitations are substantial.
- Mice are not people. Mouse liver metabolism, diet responses, and drug handling differ considerably from humans.
- Single sex and strain. Only aged female C57BL/6 mice were used. The results may not carry over to males, other strains, or postmenopausal women in any predictable way.
- Unequal delivery. MitoQ was given orally and SS-31 by injection, at very different mg/kg doses. Differences in absorption, tissue exposure, and potency make a true like-for-like comparison impossible.
- Mostly protein-level readouts. The abstract emphasizes western blot markers and histology. Those are informative, but they are not clinical outcomes like liver stiffness, fibrosis stage, or long-term events.
- Prevention-style context. Treatment occurred alongside a diet that induced disease. That is not the same as treating established MASLD in a person who has had it for years.
- Dose translation. A 25 mg/kg/day mouse dose does not convert directly to a human supplement dose. Standard body-surface-area scaling typically lowers it by roughly an order of magnitude, and that still may not match what a typical capsule provides.
Practical Takeaways
If you are curious about MitoQ: it is commercially available as a supplement, which makes it the more accessible of the two. Availability is not the same as proven benefit for liver disease. Human evidence for MitoQ in fatty liver is limited, so it should not replace established steps like weight management, diet changes, exercise, and medical follow-up. Anyone with liver disease, or taking medications, should talk to a clinician first.
If you are curious about SS-31/elamipretide: this is a prescription or investigational drug, not a supplement. Its regulatory status has been evolving and is tied to specific rare mitochondrial indications, so check current labeling rather than assuming. It is not an approved treatment for MASLD.
A caution on the research-peptide market: SS-31 is widely sold online as a "research peptide." Products in that market often lack verified identity, purity, sterility, or dosing. Injecting an unverified compound based on a mouse paper is a real safety risk. The study used a controlled laboratory compound under a defined protocol, which is not what a gray-market vial guarantees.
Bottom Line
The most useful reading of this study is that mitochondrial support, through either antioxidant or structural routes, improved key markers of fatty liver in aged, diet-stressed mice. MitoQ showed the stronger redox profile, and SS-31 the better structural preservation. The study does not show that either one works in people, or that one is better. The next step is well-designed human trials. Until then, this is promising preclinical science and not a treatment recommendation.